Evidence map›Paper›PMID 41104976›Full record

ReviewRadiology. Imaging cancer2025

Metastatic Meningioma: Neuroradiologic and Molecular Imaging Perspectives.

Pranjal Rai, Tej Mehta, Shweta S Kumar, Rebecca Choi, Sasicha Manupipatpong, Jacob Schick, Norman Beauchamp, Dhairya A Lakhani, Majid Khan

Abstract readReview
In one paragraph

Review in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pranjal RaiDepartment of Radiology, Tata Memorial Hospital, Mumbai, India.ORCID 0009-0008-3796-8273
Tej MehtaRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.ORCID 0000-0001-6866-0054
Shweta S KumarStanford Department of Radiology, Stanford, Calif.ORCID 0000-0002-0174-6301
Rebecca ChoiRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.
Sasicha ManupipatpongRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.ORCID 0000-0001-7530-3186
Jacob SchickRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.ORCID 0009-0004-2206-1274
Norman BeauchampRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.
Dhairya A LakhaniDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV.ORCID 0000-0001-7577-1887
Majid KhanRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Md.ORCID 0000-0002-3807-1387

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI JUDITH FEINBERG · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Meningiomas are the most common primary central nervous system tumors, arising from arachnoid cap cells and typically following a benign clinical course. However, a minority of cases-particularly higher-grade meningiomas-exhibit aggressive behavior, including local invasion, recurrence, and, in rare instances, extracranial metastasis. Metastatic meningioma, defined as dissemination beyond the cranial and spinal compartments, remains exceptionally uncommon, with reported incidence ranging from 0.1% to 0.76%. Common metastatic sites include the lungs, bone, liver, and lymph nodes, although virtually any organ may be involved. Proposed mechanisms of spread include hematogenous dissemination via venous sinuses, cerebrospinal fluid seeding in high-grade variants, and possibly lymphatic dissemination. Imaging features that suggest metastatic potential include irregular margins, heterogeneous enhancement, prominent peritumoral edema, and bone destruction. Advanced modalities, such as gallium 68 DOTA-Tyr3-octreotide PET/CT and fluorine 18 fluorodeoxyglucose PET, play an increasing role in detecting and characterizing both known and occult metastatic lesions. Molecular alterations, including

Indexed as

Meningeal NeoplasmsMeningiomaMolecular ImagingHumansPositron Emission Tomography Computed TomographyBrain/Brain StemDOTATATEHigh-Grade MeningiomaMeningesMetastatic MeningiomaMolecular ImagingNeuro-oncologyPeptide Receptor Radionuclide TherapySomatostatin Receptor ImagingSSTR

Identifiers

PMID41104976
PMCPMC12670024

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.